From GENES to INNOVATIVE ONCOLOGY

Luck!!!Luck!!!Luck!!!Luck!!!

~38 mln country with high level ~38 mln country with high level of genetic homogeneityof genetic homogeneity

~38 mln country with high level ~38 mln country with high level of genetic homogeneityof genetic homogeneity

PolandPolandPolandPoland

BRCA1 FOUNDER MUTATIONS BRCA1 FOUNDER MUTATIONS IN POLANDIN POLAND

BRCA1 FOUNDER MUTATIONS BRCA1 FOUNDER MUTATIONS IN POLANDIN POLAND

GÓRSKI B. ET AL.GÓRSKI B. ET AL. PATENT NO P335917PATENT NO P335917 MULTIPLEX PCR - 50€MULTIPLEX PCR - 50€

GÓRSKI B. ET AL.GÓRSKI B. ET AL. PATENT NO P335917PATENT NO P335917 MULTIPLEX PCR - 50€MULTIPLEX PCR - 50€

BRCA1 – REGISTRY BRCA1 – REGISTRY – SZCZECIN – POLAND– SZCZECIN – POLAND

BRCA1 – REGISTRY BRCA1 – REGISTRY – SZCZECIN – POLAND– SZCZECIN – POLAND

>4739 CARRIERS>4739 CARRIERS>4739 CARRIERS>4739 CARRIERS

THE LARGEST REGISTRY THE LARGEST REGISTRY IN THE WORLDIN THE WORLD

THE LARGEST REGISTRY THE LARGEST REGISTRY IN THE WORLDIN THE WORLD

Szczecin Szczecin May 11May 11, 200, 20099

Poland – limited number of founder / recurrent Poland – limited number of founder / recurrent mutations in other cancer susceptibility genesmutations in other cancer susceptibility genesPoland – limited number of founder / recurrent Poland – limited number of founder / recurrent mutations in other cancer susceptibility genesmutations in other cancer susceptibility genes

NBS1, NBS1, NOD2, NOD2, CHEK2, CHEK2, MSH2, MSH2, MLH1, MLH1, APCAPC..

NBS1, NBS1, NOD2, NOD2, CHEK2, CHEK2, MSH2, MSH2, MLH1, MLH1, APCAPC..

PENETRANCE PENETRANCE AND PROPORTION OF CANCERSAND PROPORTION OF CANCERS

PENETRANCE PENETRANCE AND PROPORTION OF CANCERSAND PROPORTION OF CANCERS

0%0%

10%10%

20%20%

30%30%

40%40%

50%50%

60%60%

70%70%

80%80%

90%90%

0%0% 20%20% 40%40% 60%60% 80%80% 100%100%

PE

NE

TR

AN

CE

PE

NE

TR

AN

CE

PROPORTIONPROPORTION

Genetic contribution to all cancers: Genetic contribution to all cancers: the first demonstration using the first demonstration using

the model of breast cancers the model of breast cancers from Poland stratifiedfrom Poland stratified by age by age at diagnosisat diagnosis and tumour pathologyand tumour pathology

Genetic contribution to all cancers: Genetic contribution to all cancers: the first demonstration using the first demonstration using

the model of breast cancers the model of breast cancers from Poland stratifiedfrom Poland stratified by age by age at diagnosisat diagnosis and tumour pathologyand tumour pathology

Lubiński J. et al. Breast Can Res Treat 15 April 2008Lubiński J. et al. Breast Can Res Treat 15 April 2008Patent US61/069,403 31.03.2009Patent US61/069,403 31.03.2009

Lubiński J. et al. Breast Can Res Treat 15 April 2008Lubiński J. et al. Breast Can Res Treat 15 April 2008Patent US61/069,403 31.03.2009Patent US61/069,403 31.03.2009

ConclusionConclusionConclusionConclusion

At present, the major significance of the At present, the major significance of the current findings is the proof of principle current findings is the proof of principle that there is that there is no cancer without a genetic no cancer without a genetic componentcomponent..

DNA analysis will be the initial starting DNA analysis will be the initial starting pointpoint for prevention, surveillance and for prevention, surveillance and treatment schemes for all adults. treatment schemes for all adults.

At present, the major significance of the At present, the major significance of the current findings is the proof of principle current findings is the proof of principle that there is that there is no cancer without a genetic no cancer without a genetic componentcomponent..

DNA analysis will be the initial starting DNA analysis will be the initial starting pointpoint for prevention, surveillance and for prevention, surveillance and treatment schemes for all adults. treatment schemes for all adults.

BRCA1 PROPHYLACTICSBRCA1 PROPHYLACTICSBRCA1 PROPHYLACTICSBRCA1 PROPHYLACTICS

Sodium selenite – clinical trialSodium selenite – clinical trial Sodium selenite – clinical trialSodium selenite – clinical trial

11343343 BRCA1 carriers BRCA1 carriers2.92.9 yrs supplementation yrs supplementation Decoding – Decoding – 07-10.07-10.20020088

New cases of cancer in the studyNew cases of cancer in the studyNew cases of cancer in the studyNew cases of cancer in the study

Placebo Selenium Total

Breast 29 41 70

Ovary 11 14 25

Fallopian 1 2 3

Peritoneal 0 1 1

Endometrial 3 3 6

Lung 1 0 1

Brain 1 0 1

Total 46 61 107

Two individuals had two cancers

Placebo Selenium Total

Breast 29 41 70

Ovary 11 14 25

Fallopian 1 2 3

Peritoneal 0 1 1

Endometrial 3 3 6

Lung 1 0 1

Brain 1 0 1

Total 46 61 107

Two individuals had two cancers

Lubiński J. et al. The Lancet Oncology 2009 (under review)Lubiński J. et al. The Lancet Oncology 2009 (under review)

Hazard ratios associated with selenium Hazard ratios associated with selenium supplementation for various cancerssupplementation for various cancers

Hazard ratios associated with selenium Hazard ratios associated with selenium supplementation for various cancerssupplementation for various cancers

Type of cancer Hazard

ratio 95% confidence

interval p-value

Primary breast cancer 1.35 0.72 - 2.51 0.35

Contralateral breast cancer 1.53 0.73 - 3.21 0.26

Ovarian/fallopian cancer 1.26 0.59 - 2.70 0.55

Any cancer 1.36 0.93 - 2.01 0.12

Type of cancer Hazard

ratio 95% confidence

interval p-value

Primary breast cancer 1.35 0.72 - 2.51 0.35

Contralateral breast cancer 1.53 0.73 - 3.21 0.26

Ovarian/fallopian cancer 1.26 0.59 - 2.70 0.55

Any cancer 1.36 0.93 - 2.01 0.12

Lubiński J. et al. The Lancet Oncology 2009 (under review)Lubiński J. et al. The Lancet Oncology 2009 (under review)

Cumulative risk of cancer (all types) among selenium Cumulative risk of cancer (all types) among selenium women randomised to selenium or placebowomen randomised to selenium or placebo

Cumulative risk of cancer (all types) among selenium Cumulative risk of cancer (all types) among selenium women randomised to selenium or placebowomen randomised to selenium or placebo

Lubiński J. et al. The Lancet Oncology 2009 (under review)Lubiński J. et al. The Lancet Oncology 2009 (under review)

Proportion of BRCA1 mutation carriers affected by breast/ovarian Proportion of BRCA1 mutation carriers affected by breast/ovarian cancers depending on selenium concentration in peripheral bloodcancers depending on selenium concentration in peripheral bloodProportion of BRCA1 mutation carriers affected by breast/ovarian Proportion of BRCA1 mutation carriers affected by breast/ovarian cancers depending on selenium concentration in peripheral bloodcancers depending on selenium concentration in peripheral blood

Selenium concentration

(μg/l) Placebo Selenium supplementation Total

Br % Ov % Br % Ov % % <30 57/0 - 57/1 1.8 30/1 3.3 30/0 - 87/2 2.3 31-40 74/3 4.1 74/0 - 39/0 - 39/0 - 113/3 2.7 41-50 97/3 3.1 97/0 - 73/2 2.7 73/0 - 170/5 3.0 51-60 71/1 1.4 71/0 - 58/4 6.9 58/0 - 129/5 3.9 61-70 46/4 8.7 46/0 - 59/3 5.1 59/2 3.4 105/9 8.6 71-80 23/6 26.1 23/1 4.3 41/4 9.8 41/1 2.4 64/12 18.8 81-90 8/3 37.5 8/2 2.5 31/5 16.1 31/0 - 39/10 25.6 91-100 5/1 20.0 5/1 20.0 22/3 13.6 22/1 4.5 27/6 22.2 >100 5/2 40.0 5/1 20.0 30/9 30.0 30/5 16.7 35/17 48.6 Total 386/23 6.0 386/5 1.6 383/31 8.1 383/9 2.3

Selenium concentration

(μg/l) Placebo Selenium supplementation Total

Br % Ov % Br % Ov % % <30 57/0 - 57/1 1.8 30/1 3.3 30/0 - 87/2 2.3 31-40 74/3 4.1 74/0 - 39/0 - 39/0 - 113/3 2.7 41-50 97/3 3.1 97/0 - 73/2 2.7 73/0 - 170/5 3.0 51-60 71/1 1.4 71/0 - 58/4 6.9 58/0 - 129/5 3.9 61-70 46/4 8.7 46/0 - 59/3 5.1 59/2 3.4 105/9 8.6 71-80 23/6 26.1 23/1 4.3 41/4 9.8 41/1 2.4 64/12 18.8 81-90 8/3 37.5 8/2 2.5 31/5 16.1 31/0 - 39/10 25.6 91-100 5/1 20.0 5/1 20.0 22/3 13.6 22/1 4.5 27/6 22.2 >100 5/2 40.0 5/1 20.0 30/9 30.0 30/5 16.7 35/17 48.6 Total 386/23 6.0 386/5 1.6 383/31 8.1 383/9 2.3

Lubiński J. et al. Lubiński J. et al. Patent application 2009 (pending)Patent application 2009 (pending)

Se concentration in the blood is the strong Se concentration in the blood is the strong marker of cancer risk for BRCA1 carriersmarker of cancer risk for BRCA1 carriers

Se concentration in the blood is the strong Se concentration in the blood is the strong marker of cancer risk for BRCA1 carriersmarker of cancer risk for BRCA1 carriers

PLACEBOPLACEBOPLACEBOPLACEBO

<50<50169/4169/4

5050134/18134/18

μμg/lg/l

p = 0.0002; OR = 6.4; CI – 2.1 – 19.4p = 0.0002; OR = 6.4; CI – 2.1 – 19.4

Lubiński J. et al. Lubiński J. et al. Patent application 2009 (pending)Patent application 2009 (pending)

Genotypes associated Genotypes associated with sensitivity to Se?with sensitivity to Se?Genotypes associated Genotypes associated with sensitivity to Se?with sensitivity to Se?

6 candidate genes 6 candidate genes (13 variants) involved (13 variants) involved

in Se metabolismin Se metabolism

Gene XGene XGene XGene X

Genotype

X1 X2

Se conc.

Se Pl Se Pl

< 75 μg/l 68/1 97/3 128/7 177/7

75 μg/l 26/2* 12/7* 70/16 14/5

Total 94/3** 109/10** 198/23** 191/12**

* 26/2 vs 12/7; p=0.0017; OR=16.8; CI=2.65-106.2 ** 10/3 vs. 12/23; p=0.011; OR=6.4; CI=1.47-27.7

Genotype

X1 X2

Se conc.

Se Pl Se Pl

< 75 μg/l 68/1 97/3 128/7 177/7

75 μg/l 26/2* 12/7* 70/16 14/5

Total 94/3** 109/10** 198/23** 191/12**

* 26/2 vs 12/7; p=0.0017; OR=16.8; CI=2.65-106.2 ** 10/3 vs. 12/23; p=0.011; OR=6.4; CI=1.47-27.7

BRCA1 carriers should consider BRCA1 carriers should consider the options of:the options of:a)a) Supplementation with Sel-BRCA1Supplementation with Sel-BRCA1®®

if they have X1 genotypeif they have X1 genotypeb)b) Lowering of Se level (diet, pharmaceuticals) Lowering of Se level (diet, pharmaceuticals)

if they are X2 and Se level is above 50 if they are X2 and Se level is above 50 μμg/lg/l

BRCA1 carriers should consider BRCA1 carriers should consider the options of:the options of:a)a) Supplementation with Sel-BRCA1Supplementation with Sel-BRCA1®®

if they have X1 genotypeif they have X1 genotypeb)b) Lowering of Se level (diet, pharmaceuticals) Lowering of Se level (diet, pharmaceuticals)

if they are X2 and Se level is above 50 if they are X2 and Se level is above 50 μμg/lg/l

CONCLUSIONCONCLUSIONCONCLUSIONCONCLUSION

PROSTATE CANCER RISKPROSTATE CANCER RISKDNA testingDNA testing

PROSTATE CANCER RISKPROSTATE CANCER RISKDNA testingDNA testing

≥ ≥ 1 prostate cancer among relatives 1 prostate cancer among relatives + +

CHEK 2, NBS 1 or BRCA 1 (C61G, CHEK 2, NBS 1 or BRCA 1 (C61G, 4153 delA) 4153 delA)

~10× increased risk ~10× increased risk

PSA, saturation biopsiesPSA, saturation biopsies

≥ ≥ 1 prostate cancer among relatives 1 prostate cancer among relatives + +

CHEK 2, NBS 1 or BRCA 1 (C61G, CHEK 2, NBS 1 or BRCA 1 (C61G, 4153 delA) 4153 delA)

~10× increased risk ~10× increased risk

PSA, saturation biopsiesPSA, saturation biopsies

Type of CHTH

No of patients

CR PR No

response BRCA1 – 44

AT 15 0 6 9 Another types 29 4 25 0

Total 44 4 31 9 Non-BRCA1 – 41

AT 12 0 12 0 Another types 29 2 25 2

Total 41 2 37 2

Type of CHTH

No of patients

CR PR No

response BRCA1 – 44

AT 15 0 6 9 Another types 29 4 25 0

Total 44 4 31 9 Non-BRCA1 – 41

AT 12 0 12 0 Another types 29 2 25 2

Total 41 2 37 2

Breast cancers with BRCA1 Treatment Breast cancers with BRCA1 Treatment – Neo-Adjuvant therapy– Neo-Adjuvant therapy

Breast cancers with BRCA1 Treatment Breast cancers with BRCA1 Treatment – Neo-Adjuvant therapy– Neo-Adjuvant therapy

Byrski T et al.: Br Ca Res Treat 2007Byrski T et al.: Br Ca Res Treat 2007

BRCA1 breast cancer cell lines BRCA1 breast cancer cell lines - resistance to taxans resistance to taxans - sensitivity to cis-platinumsensitivity to cis-platinum

BRCA1 breast cancer cell lines BRCA1 breast cancer cell lines - resistance to taxans resistance to taxans - sensitivity to cis-platinumsensitivity to cis-platinum

TREATMENTTREATMENTTREATMENTTREATMENT

Response to treatmentResponse to treatmentResponse to treatmentResponse to treatmentResponse No. %

Clinical response Complete response 9 90 Partial response 1 10 No change 0 0 Progressive disease 0 0

Pathologic response Complete pathologic response 9 90 Partial reseponse 1 10 No response 0 0

Residual disease in breast None 10 100 <1 cm 0 0 1–3 cm 0 0 4–9 cm 0 0 >9 cm 0 0

Number of lymph nodes positive 0 9 90 1–3 1 10 4–9 0 0 >9 0 0

Response No. % Clinical response

Complete response 9 90 Partial response 1 10 No change 0 0 Progressive disease 0 0

Pathologic response Complete pathologic response 9 90 Partial reseponse 1 10 No response 0 0

Residual disease in breast None 10 100 <1 cm 0 0 1–3 cm 0 0 4–9 cm 0 0 >9 cm 0 0

Number of lymph nodes positive 0 9 90 1–3 1 10 4–9 0 0 >9 0 0

Numbers of patients treated with, Numbers of patients treated with, and responding to different chemotherapyand responding to different chemotherapy regimensregimens

Numbers of patients treated with, Numbers of patients treated with, and responding to different chemotherapyand responding to different chemotherapy regimensregimens

Regimen Number treated Number of PCR %PCR

CMF 14 1 7%

AC 23 5 22%

FAC 28 6 21%

AT 25 2 8%

Cis-platinum 12 10 83%

C: cyclophosphamide M: methotrexate F: 5-flourouracil A: adriamycin (doxorubicin) T: docetaxel CMF: category includes four patients with CMFP and two patients with

CMFVP

Regimen Number treated Number of PCR %PCR

CMF 14 1 7%

AC 23 5 22%

FAC 28 6 21%

AT 25 2 8%

Cis-platinum 12 10 83%

C: cyclophosphamide M: methotrexate F: 5-flourouracil A: adriamycin (doxorubicin) T: docetaxel CMF: category includes four patients with CMFP and two patients with

CMFVP

Byrski T. et al. J Clin Oncol 2009 (accepted)Byrski T. et al. J Clin Oncol 2009 (accepted)

Prophylactic adnexectomyProphylactic adnexectomy TamoxifenTamoxifen ChemotherapyChemotherapy

Prophylactic adnexectomyProphylactic adnexectomy TamoxifenTamoxifen ChemotherapyChemotherapy

DIFFERENCES IN TREATMENT DIFFERENCES IN TREATMENT OF BRCA1 BREAST CANCERSOF BRCA1 BREAST CANCERSDIFFERENCES IN TREATMENT DIFFERENCES IN TREATMENT OF BRCA1 BREAST CANCERSOF BRCA1 BREAST CANCERS

FURTHER INVESTIGATIONSFURTHER INVESTIGATIONSFURTHER INVESTIGATIONSFURTHER INVESTIGATIONS

Monotherapy with cis-platinum Monotherapy with cis-platinum of BRCA-1 dependant:of BRCA-1 dependant:1. Disseminated breast cancers1. Disseminated breast cancers2. Cancers of other sites2. Cancers of other sites

Monotherapy with cis-platinum Monotherapy with cis-platinum of BRCA-1 dependant:of BRCA-1 dependant:1. Disseminated breast cancers1. Disseminated breast cancers2. Cancers of other sites2. Cancers of other sites

CHEMOTHERAPYCHEMOTHERAPYCHEMOTHERAPYCHEMOTHERAPY

Known drugs but selected Known drugs but selected for sub-groups of patients !!!for sub-groups of patients !!!

New drugs created against New drugs created against constitutional changes !!!constitutional changes !!!

Known drugs but selected Known drugs but selected for sub-groups of patients !!!for sub-groups of patients !!!

New drugs created against New drugs created against constitutional changes !!!constitutional changes !!!

ADVANTAGESADVANTAGESADVANTAGESADVANTAGES

Cancer bio-bank probably the largest Cancer bio-bank probably the largest in the world with biological samples in the world with biological samples and clinical data from > 200 000 cancer and clinical data from > 200 000 cancer patients, relatives and controls.patients, relatives and controls.

Exclusive access basing on agreement Exclusive access basing on agreement with its owner – IHCC, PMU, Szczecin with its owner – IHCC, PMU, Szczecin PolandPoland

Cancer bio-bank probably the largest Cancer bio-bank probably the largest in the world with biological samples in the world with biological samples and clinical data from > 200 000 cancer and clinical data from > 200 000 cancer patients, relatives and controls.patients, relatives and controls.

Exclusive access basing on agreement Exclusive access basing on agreement with its owner – IHCC, PMU, Szczecin with its owner – IHCC, PMU, Szczecin PolandPoland

ADVANTAGESADVANTAGESADVANTAGESADVANTAGES

Very unique system for scientific Very unique system for scientific progress at IHCC on elaboration of new: progress at IHCC on elaboration of new: diagnostic genetic tests, supplements diagnostic genetic tests, supplements for cancer prevention, treatment for cancer prevention, treatment protocols, drugsprotocols, drugs Homogenous Polish population Homogenous Polish population

– very low cost of genetic studies– very low cost of genetic studies Infrastructure of IHCCInfrastructure of IHCC

Very unique system for scientific Very unique system for scientific progress at IHCC on elaboration of new: progress at IHCC on elaboration of new: diagnostic genetic tests, supplements diagnostic genetic tests, supplements for cancer prevention, treatment for cancer prevention, treatment protocols, drugsprotocols, drugs Homogenous Polish population Homogenous Polish population

– very low cost of genetic studies– very low cost of genetic studies Infrastructure of IHCCInfrastructure of IHCC

LATESTS ACHIEVEMENTS LATESTS ACHIEVEMENTS LATESTS ACHIEVEMENTS LATESTS ACHIEVEMENTS

5 signed agreements on clinical trials5 signed agreements on clinical trials 5 approved international patents5 approved international patents realisation of research project financed by realisation of research project financed by

Polish Ministry of Science (60%) – from Polish Ministry of Science (60%) – from October 2008October 2008

large investments in R&D structure – large investments in R&D structure – European projectsEuropean projects

selling of counselling/DNA tests via Internetselling of counselling/DNA tests via Internet

5 signed agreements on clinical trials5 signed agreements on clinical trials 5 approved international patents5 approved international patents realisation of research project financed by realisation of research project financed by

Polish Ministry of Science (60%) – from Polish Ministry of Science (60%) – from October 2008October 2008

large investments in R&D structure – large investments in R&D structure – European projectsEuropean projects

selling of counselling/DNA tests via Internetselling of counselling/DNA tests via Internet

READ GENEREAD GENEREAD GENEREAD GENE

Stock exchange Warszawa Stock exchange Warszawa – New Connect:– New Connect:

12.02.2009 12.02.2009 2.70 PLN 2.70 PLN 11.05.2009 11.05.2009 4,35 PLN 4,35 PLN

Stock exchange Warszawa Stock exchange Warszawa – New Connect:– New Connect:

12.02.2009 12.02.2009 2.70 PLN 2.70 PLN 11.05.2009 11.05.2009 4,35 PLN 4,35 PLN 61%61%61%61%

PLANS FOR 2009PLANS FOR 2009PLANS FOR 2009PLANS FOR 2009

Income: ~ 1 500 000 PLNIncome: ~ 1 500 000 PLN

Profit: ~ 500 000 PLNProfit: ~ 500 000 PLN

Income: ~ 1 500 000 PLNIncome: ~ 1 500 000 PLN

Profit: ~ 500 000 PLNProfit: ~ 500 000 PLN

PLANS FOR 2009PLANS FOR 2009PLANS FOR 2009PLANS FOR 2009

Major investment:Major investment: Construction of R&D Read-Gene centre Construction of R&D Read-Gene centre

with laboratories (diagnostics, research) with laboratories (diagnostics, research) outpatient and chemotherapy clinicsoutpatient and chemotherapy clinics

8 000 000 PLN8 000 000 PLN 60% - structural funds – Innovative 60% - structural funds – Innovative

Economy Operational ProgrammeEconomy Operational Programme

Major investment:Major investment: Construction of R&D Read-Gene centre Construction of R&D Read-Gene centre

with laboratories (diagnostics, research) with laboratories (diagnostics, research) outpatient and chemotherapy clinicsoutpatient and chemotherapy clinics

8 000 000 PLN8 000 000 PLN 60% - structural funds – Innovative 60% - structural funds – Innovative

Economy Operational ProgrammeEconomy Operational Programme

Main task: global leadership in cancer Main task: global leadership in cancer chemopreventionchemoprevention

READ GENE SAREAD GENE SAREAD GENE SAREAD GENE SA

MAJOR GOALS 5-10 y: PROFITMAJOR GOALS 5-10 y: PROFITMAJOR GOALS 5-10 y: PROFITMAJOR GOALS 5-10 y: PROFIT

Clinical trialsDNA testingNetwork of outpatient clinicsChemoprevention main goalTOTAL: > 4 000 000 EUR per/year

Welcome for collaboration…Welcome for collaboration…

Welcome for collaboration Welcome for collaboration - 48 602 784 784- 48 602 784 784- e-mail: - e-mail: office@read-gene.com- - www.read-gene.com- www.hereditarycancer.net- www.hereditarycancer.net

Welcome for collaboration Welcome for collaboration - 48 602 784 784- 48 602 784 784- e-mail: - e-mail: office@read-gene.com- - www.read-gene.com- www.hereditarycancer.net- www.hereditarycancer.net

READ-GENEREAD-GENEREAD-GENEREAD-GENE

Read-Gene SA, 2008Read-Gene SA, 2008Read-Gene SA, 2008Read-Gene SA, 2008

Jaki wpływ ma patent na polską Jaki wpływ ma patent na polską innowacyjną gospodarkę? innowacyjną gospodarkę?

A jaki ma wpływ innowacyjność A jaki ma wpływ innowacyjność w Państwa przedsiębiorstwie ?w Państwa przedsiębiorstwie ?

Jaki wpływ ma patent na polską Jaki wpływ ma patent na polską innowacyjną gospodarkę? innowacyjną gospodarkę?

A jaki ma wpływ innowacyjność A jaki ma wpływ innowacyjność w Państwa przedsiębiorstwie ?w Państwa przedsiębiorstwie ?

Fundamentalny — jest to najlepsza Fundamentalny — jest to najlepsza forma uwiarygodnienia innowacyjności forma uwiarygodnienia innowacyjności produktuproduktu

Fundamentalny — jest to najlepsza Fundamentalny — jest to najlepsza forma uwiarygodnienia innowacyjności forma uwiarygodnienia innowacyjności produktuproduktu

Jaki wpływ ma patent na Państwa Jaki wpływ ma patent na Państwa działalność – rola i znaczenie działalność – rola i znaczenie

ochrony własności intelektualnej ochrony własności intelektualnej w Państwa działalności ?w Państwa działalności ?

Jaki wpływ ma patent na Państwa Jaki wpływ ma patent na Państwa działalność – rola i znaczenie działalność – rola i znaczenie

ochrony własności intelektualnej ochrony własności intelektualnej w Państwa działalności ?w Państwa działalności ?

Fundamentalny — testy DNA, Fundamentalny — testy DNA, farmaceutyki muszą być zabezpieczone farmaceutyki muszą być zabezpieczone patentamipatentami

Fundamentalny — testy DNA, Fundamentalny — testy DNA, farmaceutyki muszą być zabezpieczone farmaceutyki muszą być zabezpieczone patentamipatentami

Ocena skuteczności, efektywności Ocena skuteczności, efektywności i zasadności prowadzonej i zasadności prowadzonej

polityki innowacyjnej polityki innowacyjnej w odniesieniu do patentóww odniesieniu do patentów

Ocena skuteczności, efektywności Ocena skuteczności, efektywności i zasadności prowadzonej i zasadności prowadzonej

polityki innowacyjnej polityki innowacyjnej w odniesieniu do patentóww odniesieniu do patentów

Programy: Min. Nauki, PARP Programy: Min. Nauki, PARP Bardzo duże ograniczenia Bardzo duże ograniczenia Np. aplikacje 2x w rokuNp. aplikacje 2x w roku Brak pokrycia kosztów postępowania Brak pokrycia kosztów postępowania

już rozpoczętegojuż rozpoczętego Zbyt duży udział własnyZbyt duży udział własny

Brak systemuBrak systemu

Programy: Min. Nauki, PARP Programy: Min. Nauki, PARP Bardzo duże ograniczenia Bardzo duże ograniczenia Np. aplikacje 2x w rokuNp. aplikacje 2x w roku Brak pokrycia kosztów postępowania Brak pokrycia kosztów postępowania

już rozpoczętegojuż rozpoczętego Zbyt duży udział własnyZbyt duży udział własny

Brak systemuBrak systemu

Ocena skuteczności, efektywności Ocena skuteczności, efektywności i zasadności prowadzonej i zasadności prowadzonej

polityki innowacyjnej polityki innowacyjnej w odniesieniu do patentóww odniesieniu do patentów

Ocena skuteczności, efektywności Ocena skuteczności, efektywności i zasadności prowadzonej i zasadności prowadzonej

polityki innowacyjnej polityki innowacyjnej w odniesieniu do patentóww odniesieniu do patentów

Brak systemuBrak systemu

Innowacje w fazie patentowania i początkowych Innowacje w fazie patentowania i początkowych prac przed szeroką komercjalizacją muszą być prac przed szeroką komercjalizacją muszą być realizowane przez badaczy (nie przedsiębiorców) realizowane przez badaczy (nie przedsiębiorców) i dlatego wymagają wsparcia państwai dlatego wymagają wsparcia państwa

Brak systemuBrak systemu

Innowacje w fazie patentowania i początkowych Innowacje w fazie patentowania i początkowych prac przed szeroką komercjalizacją muszą być prac przed szeroką komercjalizacją muszą być realizowane przez badaczy (nie przedsiębiorców) realizowane przez badaczy (nie przedsiębiorców) i dlatego wymagają wsparcia państwai dlatego wymagają wsparcia państwa

Jakie korzyści niesie za sobą patent?Jakie korzyści niesie za sobą patent?

Straty, czy korzyści ?Straty, czy korzyści ?

Jakie korzyści niesie za sobą patent?Jakie korzyści niesie za sobą patent?

Straty, czy korzyści ?Straty, czy korzyści ?

tylko korzyścitylko korzyści odkryć, których ujawnienie może odkryć, których ujawnienie może

przynieść straty nie patentujemyprzynieść straty nie patentujemy

tylko korzyścitylko korzyści odkryć, których ujawnienie może odkryć, których ujawnienie może

przynieść straty nie patentujemyprzynieść straty nie patentujemy